

**In the Specification:**

Please amend the specification as follows. For the Examiner's convenience, a marked up version of paragraphs in the specification is enclosed (Exhibit A), in which text added to these claims is underlined and text deleted is struck through. A version of amended paragraphs in the specification as of the instant amendment is enclosed as well (Exhibit B).

On page 9, please amend the paragraph beginning on line 8 to read as follows:

Also considered within the scope of the invention is a nucleic acid molecule that: hybridizes under stringent conditions to cDNA sequence contained within ATCC Accession No. 98367; hybridizes under stringent conditions to cDNA sequence contained within ATCC Accession No. 98368; is 85% identical to SEQ ID NO:1B (Figures 3A-1 to 3C); is 85% identical to SEQ ID NO:3B (Figures 4A-1 to 4C); is 95% identical to SEQ ID NO:1B; is 95% identical to SEQ ID NO:3B; is 85% identical to cDNA sequence contained within ATCC Accession No. 98367; is 85% identical to cDNA sequence contained within ATCC Accession No. 98368; is 95% identical to cDNA sequence contained within ATCC Accession No. 98367; is 95% identical to cDNA sequence contained within ATCC Accession No. 98368; hybridizes under stringent conditions to nucleotides 128 to 1447 of SEQ ID NO:1B (Figures 3A-1 to 3C); or hybridizes under stringent conditions to nucleotides 128 to 1360 of SEQ ID NO:3B (Figures 4A-1 to 4C). Polypeptides encoded by these nucleic acids are also considered within the scope of the invention.

On page 10, please amend the paragraph beginning on line 24 to read as follows:

The invention also features substantially pure or isolated huchordin polypeptides, including those that correspond to various functional domains of huchordin, or fragments thereof. The polypeptides of the invention encompass amino acid sequences that are substantially identical to the amino acid sequence shown in Figures 6A-1 to 6C-2 (SEQ ID NO:2D).

On page 19, please amend the five paragraphs beginning on line 16 to read as follows:

Figures 3A-1 to 3C are a representation of the nucleic acid sequence of Tango-63d (SEQ ID NO:1B; open reading frame from nucleotide 128-1450) and the amino acid sequence of the polypeptide it encodes (SEQ ID NO:2B).

Figures 4A-1 to 4C are a representation of the nucleic acid sequence of Tango-63e (SEQ ID NO:3B; open reading frame from nucleotide 128-1363) and the amino acid sequence of the polypeptide it encodes (SEQ ID NO:4B ).

Figures 5A-1 to 5B are a depiction of the nucleotide sequence encoding Tango-67 and 3' and 5' non-translated sequence (SEQ ID NO:1C; open reading from nucleotide 182-853) and the amino acid sequence (SEQ ID NO:2C) of Tango-67.

Figures 6A-1 to 6C-2 are a depiction of the sequence of a cDNA encoding huchordin (SEQ ID NO:1D; open reading from nucleotide 1-2604) and the deduced amino sequence (SEQ ID NO:2D) of huchordin.

Figures 7A-7C are an alignment of a portion of the amino acid sequence of huchordin (upper sequence of each pair) and a portion of amino acid sequence of *Xenopus* chordin (lower sequence of each pair; SEQ ID NO:4D).

On page 44, please amend the paragraph beginning on line 27 to read as follows:

Two different forms of Tango-63 have been identified in the prostate cDNA library through EST sequencing and screening of the lambda phage library for the isolation of additional clones (Tango-63d and Tango-63e). Tango-63d encodes a polypeptide of 440 amino acids (encoded by nucleotides 128 to 1447 of SEQ ID NO:1B and shown in Figures 3A-1 to 3C); and Tango-63e encodes a polypeptide of 411 amino acids (encoded by nucleotides 128 to 1360 of SEQ ID NO:3B and shown in Figures 4A-1 to 4C). The polypeptide encoded by Tango-63e is identical to that encoded by Tango-63d, with the exception of the deletion of amino acids 183-211 (encoded by nucleotides 677-760) in the Tango-63d sequence. The deleted amino acids are those just amino-terminal to the transmembrane domain in Tango-63d. Tango-63d and Tango-63e are novel polypeptides that represent new members of the tumor necrosis factor (TNF) receptor superfamily.

On page 51, please amend the two paragraphs beginning on line 8 to read as follows: